What SEC filings does Immunovant, Inc. submit to the SEC?

Immunovant, Inc. (IMVT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about IMVT?

A Form 4 for IMVT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Immunovant, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for IMVT?

The 10-K is Immunovant, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all IMVT SEC filings directly on EDGAR?

You can view all historical Immunovant, Inc. filings on the SEC EDGAR company page for IMVT. Each filing card on this page links directly to the original SEC document.

How often does Immunovant, Inc. file with the SEC?

Immunovant, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling IMVT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

IMVT SEC Filing News — Immunovant, Inc.

Latest SEC filings for Immunovant, Inc. (IMVT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-09.

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovan…

Sector: Healthcare Industry: Biotechnology Market Cap: $5.7B CIK: 1764013

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for IMVT currently lean bearish. Of the 20 filing records displayed, 17 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

IMVT Filing Activity Snapshot 2026-06-26 — 2026-10-09

Insider Transactions (Form 4)

0 buys vs 17 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.53M

Stout Jay S (Chief Technology Officer) · 2026-06-26

40,000 shares · Form 4

Insider Transactions 17 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 17 filings in this group are Form 4s for Immunovant, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 17 insider filings shown, the breakdown is 17 open-market sale. 17 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×17: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-10-09

IMVT insider Stout Jay S (Chief Technology Officer) sold 3,809 shares (~$122.1K)

Stout Jay S, listed as Chief Technology Officer at Immunovant, Inc., reported an open-market sale of 3,809 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,213	$32.06	$70.9K
`S`	Open-market sale	1,596	$32.06	$51.2K

Filing: Form 4 (Insider Transaction) Insider: Stout Jay S (Chief Technology Officer) Shares: 3,809 Est. Value: $122.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-09

IMVT insider Van Tuyl Christopher (Chief Legal Officer) sold 1,327 shares (~$42.5K)

Van Tuyl Christopher, listed as Chief Legal Officer at Immunovant, Inc., reported an open-market sale of 1,327 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,327	$32.06	$42.5K

Filing: Form 4 (Insider Transaction) Insider: Van Tuyl Christopher (Chief Legal Officer) Shares: 1,327 Est. Value: $42.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-09

IMVT insider Gloria Melanie (Chief Operating Officer) sold 2,241 shares (~$71.8K)

Gloria Melanie, listed as Chief Operating Officer at Immunovant, Inc., reported an open-market sale of 2,241 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,241	$32.06	$71.8K

Filing: Form 4 (Insider Transaction) Insider: Gloria Melanie (Chief Operating Officer) Shares: 2,241 Est. Value: $71.8K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-10-05

IMVT insider Venker Eric (Director, Chief Executive Officer) sold 3,506 shares (~$119.6K)

Venker Eric, listed as Director, Chief Executive Officer at Immunovant, Inc., reported an open-market sale of 3,506 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	92,187	$14.46	$1.33M
`D`	Disposition to issuer	85,886	$33.65	$2.89M
`S`	Open-market sale	3,506	$34.11	$119.6K
`M`	Option exercise derivative · Capped Value Appreciation Rights	92,187	—	—

Filing: Form 4 (Insider Transaction) Insider: Venker Eric (Director, Chief Executive Officer) Shares: 3,506 Est. Value: $119.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-25

IMVT insider Van Tuyl Christopher (Chief Legal Officer) sold 2,846 shares (~$103.5K)

Van Tuyl Christopher, listed as Chief Legal Officer at Immunovant, Inc., reported an open-market sale of 2,846 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,846	$36.36	$103.5K

Filing: Form 4 (Insider Transaction) Insider: Van Tuyl Christopher (Chief Legal Officer) Shares: 2,846 Est. Value: $103.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-28

IMVT insider Pande Atul (Director) sold 1,500 shares (~$64.9K)

Pande Atul, listed as Director at Immunovant, Inc., reported an open-market sale of 1,500 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,500	$8.43	$12.6K
`S`	Open-market sale	1,500	$43.27	$64.9K
`M`	Option exercise derivative · Stock Option (right to buy)	1,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Pande Atul (Director) Shares: 1,500 Est. Value: $64.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-21

IMVT insider Gloria Melanie (Chief Operating Officer) sold 3,056 shares (~$135.0K)

Gloria Melanie, listed as Chief Operating Officer at Immunovant, Inc., reported an open-market sale of 3,056 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	3,056	$44.16	$135.0K

Filing: Form 4 (Insider Transaction) Insider: Gloria Melanie (Chief Operating Officer) Shares: 3,056 Est. Value: $135.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-24

IMVT insider Pande Atul (Director) sold 1,500 shares (~$59.7K)

Pande Atul, listed as Director at Immunovant, Inc., reported an open-market sale of 1,500 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,500	$8.43	$12.6K
`S`	Open-market sale	1,500	$39.80	$59.7K
`M`	Option exercise derivative · Stock Option (right to buy)	1,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Pande Atul (Director) Shares: 1,500 Est. Value: $59.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-24

IMVT insider Girao Tiago (Chief Financial Officer) sold 6,798 shares (~$263.0K)

Girao Tiago, listed as Chief Financial Officer at Immunovant, Inc., reported an open-market sale of 6,798 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	6,798	$38.69	$263.0K

Filing: Form 4 (Insider Transaction) Insider: Girao Tiago (Chief Financial Officer) Shares: 6,798 Est. Value: $263.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-24

IMVT insider Stout Jay S (Chief Technology Officer) sold 2,857 shares (~$110.5K)

Stout Jay S, listed as Chief Technology Officer at Immunovant, Inc., reported an open-market sale of 2,857 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	2,857	$38.69	$110.5K

Filing: Form 4 (Insider Transaction) Insider: Stout Jay S (Chief Technology Officer) Shares: 2,857 Est. Value: $110.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-10

IMVT insider Gloria Melanie (Chief Operating Officer) sold 2,036 shares (~$80.5K)

Gloria Melanie, listed as Chief Operating Officer at Immunovant, Inc., reported an open-market sale of 2,036 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,930	$39.53	$76.3K
`S`	Open-market sale	106	$39.99	$4.2K

Filing: Form 4 (Insider Transaction) Insider: Gloria Melanie (Chief Operating Officer) Shares: 2,036 Est. Value: $80.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-10

IMVT insider Van Tuyl Christopher (Chief Legal Officer) sold 1,206 shares (~$47.7K)

Van Tuyl Christopher, listed as Chief Legal Officer at Immunovant, Inc., reported an open-market sale of 1,206 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,143	$39.53	$45.2K
`S`	Open-market sale	63	$39.99	$2.5K

Filing: Form 4 (Insider Transaction) Insider: Van Tuyl Christopher (Chief Legal Officer) Shares: 1,206 Est. Value: $47.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-10

IMVT insider Stout Jay S (Chief Technology Officer) sold 3,487 shares (~$137.9K)

Stout Jay S, listed as Chief Technology Officer at Immunovant, Inc., reported an open-market sale of 3,487 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,906	$39.53	$75.3K
`S`	Open-market sale	105	$39.99	$4.2K
`S`	Open-market sale	1,399	$39.53	$55.3K
`S`	Open-market sale	77	$39.99	$3.1K

Filing: Form 4 (Insider Transaction) Insider: Stout Jay S (Chief Technology Officer) Shares: 3,487 Est. Value: $137.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-06

IMVT insider Venker Eric (Director, Chief Executive Officer) sold 3,092 shares (~$119.0K)

Venker Eric, listed as Director, Chief Executive Officer at Immunovant, Inc., reported an open-market sale of 3,092 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	92,188	$14.46	$1.33M
`D`	Disposition to issuer	86,629	$38.14	$3.30M
`S`	Open-market sale	3,092	$38.48	$119.0K
`M`	Option exercise derivative · Capped Value Appreciation Rights	92,188	—	—

Filing: Form 4 (Insider Transaction) Insider: Venker Eric (Director, Chief Executive Officer) Shares: 3,092 Est. Value: $119.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-26

IMVT insider Gloria Melanie (Chief Operating Officer) sold 17,714 shares (~$678.6K)

Gloria Melanie, listed as Chief Operating Officer at Immunovant, Inc., reported an open-market sale of 17,714 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	14,748	$38.18	$563.1K
`S`	Open-market sale	2,966	$38.95	$115.5K

Filing: Form 4 (Insider Transaction) Insider: Gloria Melanie (Chief Operating Officer) Shares: 17,714 Est. Value: $678.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-26

IMVT insider Stout Jay S (Chief Technology Officer) sold 40,000 shares (~$1.53M)

Stout Jay S, listed as Chief Technology Officer at Immunovant, Inc., reported an open-market sale of 40,000 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	33,277	$38.18	$1.27M
`S`	Open-market sale	6,723	$38.94	$261.8K

Filing: Form 4 (Insider Transaction) Insider: Stout Jay S (Chief Technology Officer) Shares: 40,000 Est. Value: $1.53M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-26

IMVT insider Van Tuyl Christopher (Chief Legal Officer) sold 17,824 shares (~$682.9K)

Van Tuyl Christopher, listed as Chief Legal Officer at Immunovant, Inc., reported an open-market sale of 17,824 IMVT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	17,824	$15.20	$270.9K
`S`	Open-market sale	14,982	$38.19	$572.2K
`S`	Open-market sale	2,842	$38.96	$110.7K
`M`	Option exercise derivative · Stock Option (right to buy)	17,824	—	—

Filing: Form 4 (Insider Transaction) Insider: Van Tuyl Christopher (Chief Legal Officer) Shares: 17,824 Est. Value: $682.9K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Immunovant, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-03

IMVT filed 8-K — material company event

Immunovant, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-06

IMVT filed 8-K — material company event

Immunovant, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Immunovant, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-06

IMVT filed Quarterly Report (10-Q)

Immunovant, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Immunovant, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on IMVT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — IMVT SEC Filings

More Tools for IMVT

IMVT Full Stock Analysis IMVT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper IMVT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the IMVT stock analysis page.

IMVT Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer